Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 6Phase 3 5Phase 1 4Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 4Metastatic Adenocarcinoma of the Pancreas 1

Interventions

pembrolizumab 222Carboplatin 215Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 114Cyclophosphamide 102Pemetrexed 100Dexamethasone 100Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 68durvalumab 65Lenalidomide 64Radiation 62atezolizumab 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × irinotecan sucrosofate × 1 year × Clear all
NCT06625320 2026-06-02

RASolute 302

Revolution Medicines, Inc.

Phase 3 Active not recruiting
500 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07409272 2026-06-02

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Inc

Phase 3 Recruiting
614 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06958328 2026-05-04

LAP100

NRG Oncology

Phase 3 Recruiting
356 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡